QUÉBEC CITY, March 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the “Company”) today announced poster presentations on two of its anticancer compounds, perifosine and AEZS-136, at the upcoming American Association for Cancer Research (“AACR”) meeting to be held March 31 - April 4, 2012, at the McCormick Place in Chicago.
Sunday, April 1, 2012 / 1pm- 5pm (Central)
| Abstract #871: | “Dual inhibition of PI3K and Erk1/2 shows synergy and efficacy in human tumor cells, either by using drug combinations or novel dual PI3K/Erk inhibitors”, I. Seipelt, M. Gerlach, L. Blumenstein, G. Mueller, E. Guenther, J. Engel and M. Teifel |
| Presenter: | Irene Seipelt, PhD, Director, Preclinical Development, Aeterna Zentaris |
| Session: | Experimental and Molecular Therapeutics 4 |
| Venue: | Hall F, poster section 32, McCormick Place, Chicago |
Monday, April 2, 2012 / 1pm- 5pm (Central)
| Abstract #2877: | “Perifosine alone and in combination with anti-metabolites interferes with NF-kB pathway activation in colon cancer cell lines”, B. Aicher, P. Schmidt, J. Engel, E. Guenther and M. Teifel |
| Presenter: | Babette Aicher, PhD, Director, Preclinical Development, Aeterna Zentaris |
| Session: | Experimental and Molecular Therapeutics 23 |
| Venue: | Hall F, poster section 34, McCormick Place, Chicago |
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. The Company’s innovative approach of “personalized medicine” means tailoring treatments to a patient’s specific condition and to unmet medical needs. Aeterna Zentaris’ deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.
